3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stress Disorders, Post-Traumatic
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Colorectal Neoplasms
1
Interventions
Gemcitabine
25
Cisplatin
19
pembrolizumab
11
avelumab
10
Nivolumab
7
Mitomycin
6
Carboplatin
6
apaziquone
5
Paclitaxel
5
Vinblastine
4
Methotrexate
4
Doxorubicin
4
Docetaxel
4
BCG Vaccine
4
vofatamab
3
durvalumab
3
atezolizumab
3
Sunitinib
3
Standard of Care
3
Sorafenib
3
Radiotherapy, Intensity-Modulated
3
Radiotherapy
3
Radiation
3
Magnetic Resonance Spectroscopy
3
Lapatinib
3
Cystectomy
3
B701 protein, Human herpesvirus 6
3
valrubicin
2
rucaparib
2
enfortumab vedotin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Urinary Bladder Neoplasms
×
Palliative Care
×
Clear all
NCT03652298
2026-03-13
NeuroPrevPTSD
Centre Oscar Lambret
Phase 2
Terminated
19 enrolled